Psychoneuroimmunology Therapy in Uncontrolled Diabetic Patients: A Quasi-experimental Study

NCT ID: NCT02536820

Last Updated: 2015-09-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Psychoneuroimmunotherapy (PNIT) is the study, modification and implementation of the interactions between the processes of adaptive behavior, neurological, endocrine and immune.

Among its premises assuming homeostasis or physiological balance as an integrated process involving the systems above mentioned.

Additionally, among the basics theme the re-mean is introduced, ie changing the direction, the function of a concept from a negative context carry a positive meaning, so that from the PNIT no disease is seen as a problem but as a situation to solve. The patient then transmits the importance of which will come.

Primary objective:

To investigate whether patients on PNIT have a higher proportion of patients achieving disease control (\<7% in glycosylated hemoglobin (HBAC1) and quality of life compared with conventional treatment patients.

Methodology:

quasi-experimental, simple blind, simple blind, parallel, phase III clinical trial The investigators will follow a group of patients with type 2 diabetes mellitus durgin three months with an interim analysis a month after receiving the intervention (two visits) During each visit a trained PNIT physician assess the effectiveness, safety and quality of life of each patient.

The investigators will include male or female patients aged 18 years-old with diabetes mellitus type II in any severity, uncontrolled (\> 7% Glycosilated Haemoglobin (HbAc1)) and any treatment regimen included.

The patients are not allocated by a random process and the investigators will have a convenience sample

The investigators will perform an intention to treat analysis, patients will be analyzed according to the intervention received even if this was different from the one they were assigned.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional treatment + PNIT

PNIT: Psychoneuroimmuno therapy Conventional treatment: Usual treatment that each diabetic patient recieved

Group Type OTHER

psychoneuroimmune therapy

Intervention Type BEHAVIORAL

Conventional treatment

Conventional treatment: Usual treatment that each diabetic patient recieved

Group Type ACTIVE_COMPARATOR

Conventional treatment

Intervention Type DRUG

Actual diabetes treatment in each participant

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

psychoneuroimmune therapy

Intervention Type BEHAVIORAL

Conventional treatment

Actual diabetes treatment in each participant

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Solarte Technique

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who wish to participate with informed consent sign.
* Diagnosed with uncontrolled diabetes mellitus type II (\> 7% of HbAc1) at least six months before starting the study
* No change in medication at least three months before starting the study.
* Participants with acceptable electrocardiographic results acceptable at the study start.

Exclusion Criteria

* Pregnant women, or planning to become pregnant during the study period.
* History of severe liver failure.
* Participants requiring elective surgeries or other procedures requiring general anesthesia for the duration of the study.
* Participants who are participating in other clinical trials involving drugs or who have participated in another clinical trial in the last three months.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Coomeva E.P.S

UNKNOWN

Sponsor Role collaborator

Sinergia

UNKNOWN

Sponsor Role collaborator

Fundación Salutia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PNIT2015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Managing Diabetes Mindfully Study
NCT01796834 COMPLETED NA